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ABSTRACT
A Novel Method to Commercialize Medical Devices Initially Developed at California
Polytechnic State University San Luis Obispo
Christina Grigorian
California Polytechnic State University, San Luis Obispo is a university that encourages
students to approach learning hands-on. As such, there is cutting-edge technology being
developed by students in all departments on campus. Being that the university possesses
an outstanding biomedical engineering department, there are groundbreaking medical
devices that students are creating at Cal Poly SLO. These are devices that can better the
lives of individuals suffering from ailments or fulfill needs in the medical industry.
Subsequently, it is vital that these devices make it out of campus laboratories and into the
hands of consumers. In order to move a product from ideation to the market, numerous
steps must be completed and often times, especially with the challenges of
commercializing medical devices, these efforts can result in failed product launches. As
such, there is demand for a commercialization process to be created at Cal Poly SLO that
will aid student created medical devices in reaching the market. This paper documents the
progress made thus far on such a process at Cal Poly SLO.

Key Words: Commercialization Pathway, Medical Device, Tympanostomy
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Chapter 1
INTRODUCTION
1.1 Prevalence
At California Polytechnic State University San Luis Obispo numerous biomedical
products are created in the College of Engineering (CENG) annually. These devices aim
to better the lives of people through the advancement of medical technology.

Medical devices are uniquely challenging in respect to commercialization because these
devices often require clinical trials and approval from the U.S. Food and Drug
Administration (FDA). These challenges are in addition to the traditional difficulties
surrounding new product development. To transform a medical device from prototype
into marketable device can take years and requires a plethora of resources. New
medical device production is most often completed by large medical device companies
who possess the ability to nurture the commercialization of medical devices. As a result,
cutting edge medical devices made by smaller parties often do not have the means or
knowledge required to push a medical device into market. As such, current market
needs are not being met and devices that can potentially enhance the quality of life of
groups of our population, are not being offered.

It is desirable for a university such as California Polytechnic State University San Luis
Obispo, which encourages innovation within its reputable Biomedical Engineering
department, to possess a method to commercialize medical device innovation that is
incorporated into coursework.
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1.2 Product Development Fundamentals
Product development requires the completion of five general steps. For the proposed
method of commercialization for medical devices at California Polytechnic State
University San Luis Obispo, all five phases will also need to be completed. The
fundamental five phases are as follows:
1. Idea Generation: Individuals search for ideas that can potentially be converted
into products. This may include determining a gap in the current market where
there is a need that has yet to be met. In this stage early prototyping may take
place to demonstrate an idea.
2. Screening: The feasibility of proposed product ideas are evaluated in this step.
This step aims to ensure that product ideas will only be supported if there is a
viable chance of product success.
3. Concept Development: Research is conducted to determine the specifics of the
proposed project. Aspects such as product strengths, products weaknesses,
product market, and product competitors may be explored in this phase. This
step may involve focus groups or surveying to determine what consumers require
out of a potential product or to further understand the need that is attempting to
be met. Designs are flushed out within this step.
4. Product Development: Designs for the product are created and tested. The
specifics of a design are determined and optimized. Products may be introduced
to groups of consumers in order to receive feedback on the product before it’s
official launch. Testing and device optimization will occur in this step.
5. Commercialization and Rollout: A product is marketed to its target audience and
launched into the market1.
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1.3 Current Medical Device Commercialization Pathway
There are numerous pathways that entities may take when working to commercialize
medical devices. However, there are key steps that must take place in order to launch a
medical device. Many steps of this process occur simultaneously or are revisited
throughout a commercialization process.

1.3.1 Market Assessment
Once a need in the market is determined and a potential solution is created, it is
necessary to investigate the market for this device. Determining the number of devices
that would be used annually by researching the number of procedures or cases where
such a device would be applicable is necessary to place a potential market value on the
product. It is vital to determine the other companies and competitors that are addressing
the same medical need and how large of a portion of the market each competitor
possesses.

1.3.2 Intellectual Property Securement
When attempting to commercialize a product, entities must work to secure the
intellectual property (IP) of their device to ensure that other entities do not sell their
product or pilfer an idea. In order to be assigned intellectual property, a product must be
useful, novel, and nonobvious. Companies often seek legal assistance to complete a
prior art search in which active intellectual property of similar devices is researched to
ensure that any newly created product does not infringe upon existing patents. In this
phase, a company will discover if they are able to patent their idea or if they must
complete a licensing agreement to essentially use existing intellectual property by paying
the IP owner a fee. IP filing is especially important to complete early on in

3

commercialization because patents are now assigned to the individuals who file a patent
first as opposed to who actually invented the device or idea.

1.3.3 Business Model Creation
Entities hoping to commercialize medical devices must determine how they hope to
achieve this goal. In the medical device industry, it is common practice for individual
inventors or physicians to transfer their ideas to larger biotech firms. These firms will go
on to develop and commercialize the device and will compensate the inventor. However,
many inventors chose to create their own startups to promote their inventions. Often in
this phase, gaining access to key opinion leaders and determining potential
manufacturing options also takes place. In this step, companies may want to begin
securing funding to allow for attainment of the necessary resources and for the product
launch later to come.

1.3.4 FDA Approval Securement
Medical devices fall under 3 different classes as listed in Table 1. Depending on the
class in which a product is classified, a device will require specified testing and
documentation in order to be FDA approved. Additionally, varying devices will require
that varying approval paths be completed. It is vital that a company determine their
device classification and approval submission route to ensure that the necessary
documentation, validation, and clinical trials be completed. FDA approval can be an
exceptionally time-consuming step in medical device commercialization.

4

Table 1. Medical Device Classification Chart23
Classification
Class I

Risk
Low

Class II

Moderate

Class III

High

Examples
-Surgical Instruments
-Tooth Brush
-Bandage
-Catheter
-Syringe
-Surgical Gloves
-Pacemaker
-Cochlear implant
-Defibrillator

1.3.5 Research and Development
This phase will require a multidisciplinary team’s work to create a design that account for
a device holistically. An R&D team must take into account a product’s manufacturability,
product requirements, FDA regulation, financing, and intellectual property when flushing
out a design. In this step, prototypes and beta models will be created to gain consumer
and key opinion leader feedback. Throughout the R&D process a device will undergo
numerous redesigns to ensure that the device has been optimized.

1.3.6 Device Launch:
Once a medical device has gone through all portions of the commercialization process, it
can be launched. Previous to product launch, there must be a post-market surveillance
system in place to collect data on product performance in market. Such data can be
used to later alter devices as needed4 .

5

1.4 Purpose of Thesis
The purpose of this thesis is to document a novel commercialization pathway created for
medical devices made at California Polytechnic State University San Luis Obispo. This
document will outline the commercialization method.

1.5 Scope of Thesis
In order to create the novel method proposed, it is necessary to use a medical device as
a trial run of the process. For the purposes of this thesis project, a tympanic tube device
will be used to determine the commercialization process.

6

Chapter 2
PROJECT SPECIFIC GOALS
The overall objective of this project is to create a commercialization method for medical
devices made at California Polytechnic State University San Luis Obispo. There are
seven project specific goals that must be completed in order to achieve this objective.
The goals consist of the following:
Device Optimization: The medical device design will need to be optimized in order to
meet the design requirements. The design will be frozen after optimization is complete.
Intellectual Property: A legal partner, specifically a registered patent attorney, must be
secured which will work to complete the legal documentation require to move the
product forward, most notably intellectual property assignment documentation.
Manufacturing: An ISO 13485 certified manufacturer partner must be secured which will
produce the medical device.
FDA Approval: An FDA consultant must be secured in order to provide guidance on the
FDA documentation process. This consultant will ensure that medical devices will be
approved by the FDA speedily by ensuring that all documentation is correctly and
completed filed.
Funding: A means of project funding must be secured to allow for the product
continuation and support.
Marketing Plan: A marketing plan must be created to ensure that once a device is
created, knowledge of said device reaches relevant parties.
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Chapter 3
COMMERCIALIZATION LITERATURE REVIEW
3.1 Model University Processes
Certain U.S. universities have placed an emphasis on assisting students in the
development and commercialization of products and the creation of businesses. In this
section, universities which offer such programs will be discussed and function as
potential templates from which certain elements may be beneficial towards the
development of a unique commercialization method for California Polytechnic State
University San Luis Obispo.

3.1.1 University of Notre Dame ESTEEM Program
The University of Notre Dame, located in South Bend Indiana, is home to the ESTEEM
program. This is a graduate program that focuses on not only on the study of
entrepreneurship in STEM fields but the application of entrepreneurship. Upon
completion of the ESTEEM program, students are granted a Master of Science (M.S.) in
Engineering, Science, and Technology Entrepreneurship5. This program is open to
students whom possess technical undergraduate degrees. The three-semester program
is unique as it does not focus on course assignments but rather has a capstone project
that students work on throughout the entirety of their three semesters. As concepts and
skill sets are taught through courses, students must then apply these concepts to their
capstone project in an actual effort to commercialize their project. Students are required
to take business courses as well as technical electives in order to receive their graduate
degree. Business courses cover topics such a business law, accounting, and leadership.
Such topics are not generally taught in STEM undergrad programs and the inclusion of
these courses allows for students to gain a holistic understanding of entrepreneurship in
both the business aspects and the technical and innovative aspects6 .
8

The efforts made by ESTEEM students on their capstone projects will often result in the
fruition of companies and products that will outlast a student’s time at Notre Dame.
Projects offered through the ESTEEM program leave Notre Dame with a strong
foundation to ensure success7. This program allows students to nurture a product and
gives graduates the tools they need to create successful, long-lasting businesses. By
offering a means by which students do not have to separate creating product from
academic work, the University of Notre Dame ensures that pupils graduate with far more
than just the knowledge surrounding entrepreneurship.

3.1.2 Purdue University Burton Morgan Center for Entrepreneurship
Purdue University, located in West Lafayette, Indiana, has created the Burton Morgan
Center for Entrepreneurship. This center functions to make commercialization tangible
for students and alumni. There are numerous programs offered through the center that
focus on a range of commercialization steps such as early stage product development to
product launch. All programs allow for startup companies to acquire whatever resources
they may need to become successful and reach their full potential. This center provides
legal, funding, marketing, and manufacturing resources that students need for the
successful launch of companies. This program allows MBA students to apply concepts
acquired through coursework, to actual companies and products. Similar to the ESTEEM
program, students are able to enroll in courses and programs that combine coursework
and projects hosted by the Burton Morgan Center for Entrepreneurship8. In this way
students are able to learn and apply entrepreneurial concepts and create viable
companies while also completing coursework.

The Burton Morgan Center for Entrepreneurship provides a unique opportunity for
students to leave the university with a concrete business. Students are able to propose
9

their own product ideas and develop these ideas through course work that utilizes their
own startup formation as course work9.

3.1.3 Business Creation Program UCLA
The University of California, Los Angeles offers a business creation program as part of
their full-time MBA programs. Students currently completing an MBA may choose to take
part in the business creation program that aims to launch student companies while
students are still attending university. In the first year of their MBA, students will submit
project proposals to the business creation program and complete two prerequisite
courses. Accepted proposals will begin work on their startup in their second year and will
require two quarters to plan and launch. Through these two quarters, student startups
are rapidly developed and nurtured, and each week one aspect of a student’s business
is addressed. On average, 50% of student startups that participate in this program
launch successful companies10. This program is designed to take student ideas and use
them to combine the theoretical and hands-on portions of entrepreneurship within the
required ten units of coursework. Students within this program are encouraged to forge
new ideas and combine technical fields with business concepts to develop new products
and companies and transform these ideas into profitable careers11.

3.1.4 Babson College MS in Entrepreneurial Leadership (MSEL)
Babson College housed in Wellesley, Massachusetts, is known worldwide for their
entrepreneurial programs. They currently offer an MS in Entrepreneurial Leadership
(MSEL) which aims to launch student startups as well as produce effective leaders in
industry. This nine-month, full-time MBA program allows students to work on their own
startup ideas and place their startups on the path to commercialization and long-term
success. This program holds coursework at its core to teach students the necessary
10

skills to create and launch a business. Outside the classroom, students are required to
apply this knowledge to a project to reinforce recently learned concepts12. This program
allows students to either bring in their own startup ideas or contribute to outside sponsor
proposed projects. Because of the robust entrepreneurial community at Babson College,
students have access to a plethora of resources and advisement13. A unique aspect of
this program is its focus on the leadership role necessary in business. Core classes
provide students with skills they will need as leaders in a business including negotiation,
effective communication, and talent recognition. Students within this program are able to
grow their personal skillsets as well as launch a company while in university.

3.1.5 Cal Poly’s Center for Innovation and Entrepreneurship (CIE)
California Polytechnic State University San Luis Obispo is home to the Center for
Innovation and Entrepreneurship which functions to support students with an interest in
entrepreneurship and the world of start-ups. The CIE has helped students start over 120
successful companies and provides invaluable resources such as a project workspace,
mentorship opportunities, and networking opportunities. Numerous students that
become involved with the CIE are undergraduate entrepreneurship students however
this organization welcomes students of all years and majors. Different programs to help
start student-run companies include elevator pitch competitions and accelerator
programs. The Cal Poly CIE has allocated manufacturing resources on campus, the
space is known as Innovation Sandbox, to assist student run companies prototype their
products. This program does a phenomenal job of supporting students and their
entrepreneurial endeavors.
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3.2 Unique Aspects of a Cal Poly Commercialization Method
The proposed commercialization pathway for medical devices will adopt aspects of
commercialization pathways currently offered through other universities. However, there
are two unique aspects to the pathway described in this document.

3.2.1 Ownership to Students and Sponsors
A major focus of the commercialization process to be created at California Polytechnic
State University San Luis Obispo (Cal Poly SLO) will be to ensure that students and/or
sponsors possess a majority of company ownership. Many institutions do not openly
disclose what portion of ownership the institution will collect if a company is created
through university programs and using university resources. The ambiguity of where
ownership will fall can deter students and sponsors from approaching universities for
assistance with entrepreneurial endeavors. However, the proposed commercialization
pathway hopes to encourage individuals to consider Cal Poly SLO as a resource to
reach their business goals. Typical projects that may use this pathway include senior
projects sponsored by individuals who retain all intellectual property of the project,
individual student projects, and faculty sponsored projects.

3.2.2 Specialization in Medical Devices
While this pathway would retain the capabilities necessary to commercialize non-medical
devices, it will specifically target the commercialization of medical devices. The
commercialization of medical devices can prove an exceptionally difficult process as
previously mentioned. This commercialization pathway would be unique in that it offers
students specialized support in producing viable medical devices and companies while
students are in the university.
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Chapter 4
TYMPANIC TUBE LITERATURE REVIEW
4.1 Otitis Media
Otitis Media, otherwise known as a middle ear infection, consists of swelling and
inflammation of the middle ear. Fluid and pus buildup behind the tympanic membrane,
also known as the eardrum, occurs and proper drainage of such fluid through the
Eustachian is hindered14. Figure 1 illustrates the differences between a normal middle
ear and an infected middle ear. In most cases, the bacteria that cause Otitis Media are
streptococcus pneumoniae, Moraxella catarrhalis, and non-typeable haemophilus
influenza.

Figure 1. Normal vs. Otitis Media Inner Ear15
Otitis Media can occur for a number of reasons. If an individual suffers from an upper
respiratory infection (URI) such as a cold, sinus infection, or tonsillitis, the swelling that
may occur as a result of such infections allows for bacteria to enter the Eustachian
Tube16. Changes in altitude and climate can also cause this type of infection. Otitis
Media can also occur if an individual possesses a deformed, blocked, or dysfunctional
Eustachian tube. Ears with more horizontally positioned Eustachian tubes are more
likely to suffer from Otitis Media due to increased ease for bacteria introduction to the
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middle ear14. Those who smoke, are exposed to secondhand smoke or have allergies
are at higher risk for developing Otitis Media as well. Individuals with immune
dysfunction and over activity are at risk for Otitis Media because their bodies may
produce excess amount of mucus and immune cells which may increase the
inflammation and fluid buildup behind the eardrum17.

Children are at the highest risk of suffering from Otitis Media. Individuals ranging from
birth until seven years of age account for the largest population suffering from Otitis
Media. Children have shorter, more horizontal Eustachian tubes as shown in Figure 2
and this allows for bacteria to enter the middle ear with ease. Children also possess
enlarged adenoids which can block the Eustachian tube and cause a buildup of fluids
which produces the ideal conditions for an ear infection to occur. Children who are not
breastfed or who feed while laying down often suffer from middle ear infections as well
as children who use pacifiers for prolonged periods of time18. Recent studies have
shown that children who receive the pneumococcal vaccination may be less likely to
experience middle ear infections17.

Figure 2. Infant and Adult Eustachian Tube Orientation18
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4.2 Otitis Media Symptoms

Symptoms of Otitis Media include irritation and pain in the ears. Because of the nature of
the infection, individuals may experience a loss of balance, loss of hearing, or headache.
Vomiting, fever, and diarrhea may be present in patients as well19. In severe cases,
Otitis Media can cause Mastoiditis which is an infection of the bones in the skull which
can be life threatening. Symptoms of Otitis Media can persist for months even after
treatment20.

4.3 Otitis Media Treatment Options
Currently there are a limited amount of treatment options for Otitis Media. One method of
treatment may be an Ototopical antibiotic such as Ciprofloxacin or Ofloxacin. This
treatment option proves successful for acute cases of Otitis Media21.

Another treatment option is an antibiotic prescription. Amoxicillin is most commonly
prescribed for this type of infection however in those allergic to the medicine,
clindamycin, cephalosporins, and macrolide antibiotics can be used as a substitute20.
This may be paired with an analgesic to alleviate the pain experienced from the infection
such as acetaminophen. Antibiotic treatments usually continue over a ten-day period for
optimum results17. If unsuccessful, an extended antibiotic treatment may be prescribed.

If an antibiotic treatment proves unsuccessful or if a large amount of fluid is still present
in the inner ear after the infection dissipates, a tympanostomy tube may be
recommended. These tubes allow for the fluid buildup of the infected middle ear to drain
and can help prevent future middle ear infections from occurring.
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4.4 Tympanic Tube Overview
Tympanic tubes are small tubes that are surgically implanted into the tympanic
membrane. These tubes create a direct path between the middle ear and the ear canal.
This pathway allows for the proper drainage of fluid in the middle ear as well as serves
as a means to regulate pressure within the middle ear. Tympanic tubes were first
introduced to the market in 1954 by Beverly Armstrong MD. Previous to their
introduction, a hole was punctured in the eardrum and the fluid in the eardrum was
drained via gravity. However, such drainage systems would seal rapidly as the body
healed and the infection would not entirely dissipate or would return shortly22. Today’s
tympanic tubes are able to remain implanted anywhere from three months to two years.

Tympanic tubes today are most commonly made of medical grade silicon and metal.
Although designs vary, tubes generally possess a cylindrical portion which functions as
the connector piece between the middle ear and the outer ear. Most designs also
possess flanges that function to keep the tube in place in the ear and prevent premature
exit. Figure 3 demonstrates commonly used tympanic tube designs, the collar button
(A), Triune (B), and t-tube respectively(C). The collar button and the t-tube are currently
market lead devices and are manufactured by Summit Medical38. The triune tube is not
as popular as the aforementioned tubes, however it is still very prevalent in the market
and is manufactured by Grace Medical39.

Figure 3. Commonly Used Tympanic Tubes23
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4.5 Tympanic Tube Implantation
Tympanic tubes are implanted into patients by an Ear, Nose, and Throat physician
(ENT) in a procedure called a myringotomy. This procedure is completed using either
general anesthetic or local anesthetic24. Once the proper anesthetic has been
administered, the physician will slightly puncture the eardrum to create an opening for
tube implantation. The built-up fluid within the ear will be removed as needed and an ear
tube will be placed within the incision. The tube will create a connection between the
middle ear and ear canal as the tympanic membrane heals itself around the tube.
Directly after the procedure, the ears may be plugged to absorb excess blood. This
outpatient procedure takes about 15 minutes and a patient can be in and out of the
hospital within a few hours25.

After the procedure, patients should be careful to avoid the introduction of outside fluids
such as pool water, bath water, etc. into the ear canal as this may cause additional
infections.

4.6 Issues with Current Tympanic Tube Designs
Since its’ invention, tympanic tubes have tremendously aided in alleviating Otitis Media
in patients worldwide. Although this is true, such devices come with their own set of
flaws. A major issue is perforation of the tympanic membrane. Perforation occurs when
the eardrum is unable to heal properly after a tympanic tube is removed and as a result,
the tympanic membrane is not uniform and possesses a gap. This can result in
temporary or permanent hearing loss depending on the severity of the perforation.
Depending on the model of tube used, a different level or perforation risk will be present.
However, when tubes naturally extrude, there is a very low risk of perforation of about
4%. When tubes are surgically removed this risk increases to roughly 30%26.
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Another issue with current tympanic tube designs is tube blockage. Tubes may become
blocked by Otorrhea, wax, blood, or foreign bodies27. A physician may recommend
eardrops to loosen the blockage. If unresolvable blockage occurs, a tube is no longer
able to allow for pressure regulation or middle ear fluid drainage and will require
removal. Because tympanic tubes expose the middle ear to the outside, the tube itself
may actually cause middle ear infections. The same units that may be causing blockage
in the tube may also be contributing to infections within the middle ear. As such, patients
with tympanic tubes may be advised to wear earplugs when their ears may be in contact
with water. Regular checkups every 3-6 months are necessary to assess a tube’s
functionality28.

Due to the nature of the tube, granulomas can also result from the implantation of a
tympanic tube, although this is not common. A granuloma occurs when the deepest
layer of the eardrum heals itself while the tube is implanted in the ear and blood vessels
grow throughout the aperture of the tube29. Figure 4 illustrates a small granuloma. When
this happens, these blood vessels will often rupture and bleed out into the middle ear. In
these cases, a tube will need to be surgically removed.

Figure 4. Granuloma Visualization29
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Cholesteatomas can also occur in patients who have experienced chronic otitis media
and who have had a tympanic tube implanted. Cholesteatomas often present
themselves in the form of cysts that grow behind the tympanic membrane. As these
cysts grow, they can become massive and shed layers of skin inside the middle ear.
This can result in damage to the bones within the middle ear30. Patients who experience
Cholesteatomas will often experience symptoms similar to that of patients with Otitis
Media29.

Tympanic tube patients also may experience Tympanosclerosis, which is the hardening
of the tympanic membrane due to scarring. Tympanosclerosis can occur due to many of
the aforementioned complications of tympanic tube implantation. This condition can
result in conductive hearing loss31.

4.7 Device Market Need
In the United States, it is estimated that one million tympanic tubes are implanted
annually32, representing a 90-million-dollar industry as of 201833. According to the
Children’s Hospital at Vanderbilt, seven percent of all children in the United States will
receive bilateral implantation of tympanic tubes by the age of three34. Being that the
insertion of ventilation tubes is the most common surgical procedure for children to
undergo, there is an enormous market for this medical device35. It is estimated that by
2025, the market will grow to a 102-million-dollar industry. Such growth allows for new
devices to enter the market and provide for this growing need.
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Chapter 5
METHODS
5.1 Device Optimization
Device optimization is a step in the commercialization process that will largely be
completed by the creators of the device. Bench testing and validation must be completed
to ensure that a suitable device has been created. A key part in this portion of the
process is the identification of key opinion leaders. These are individuals who are
experts in a certain subject matter. In the case of the tympanic tube, the project sponsor
Roger D. Haring was the primary key opinion leader as he is a retired Ear, Nose, and
Throat (ENT) physician. Additionally, Robert Stewart MD, who is a practicing ENT
physician in San Luis Obispo was recruited as a key opinion leader. Both individuals
have functioned as valuable sources of information in the subject matter. Their opinions
and advice have helped to optimize the tube design. As such, it would be necessary for
each device that utilizes the proposed commercialization pathway to pinpoint key opinion
leaders in the niche of biotechnology that pertains to their project. The Biomedical
Department at Cal Poly SLO has strong connections with French hospital and as such,
key opinion leader securement should be tangible in this way.

There are hundreds of tympanic tubes on the market today with varying geometries,
specialized uses and designs. In order to optimize a tympanic tube, a few design
aspects must be taken into consideration to produce an effective tube with the specified
capabilities. At the start of this project, there was a proposed design for the tympanic
tube. Modifications have been made to this design in order to optimize its function and
marketability.

20

5.1.1 Versatility
It was desirable for the tympanic tube design to be versatile in terms of the length of time
the tube would be implanted in the eardrum. Tubes with longer flanges will remain in the
eardrum for a longer period of time and the opposite is true for short flanges. In order to
accommodate both timelines, notches were added to the flanges of the tympanic tube.
These notches indicated where a physician could cut a tube’s flange to alter the length
of time a tube remained implanted.

5.1.2 Absence of Premature Extrusion
Currently many tympanic tubes prematurely extrude themselves from the eardrum. This
issue causes patients to have to undergo multiple surgeries to have the tubes reimplanted in their ears. To counter this, the once straight flanges were curved to ensure
that the flanges provided grip without damaging ear drums when implanted for extended
periods of time. Additionally, the flanges of the tympanic tube were left long. This will
allow physicians to provide patients with a tube that will remain in the ear for an
extended period of time without falling out.

5.1.3 Aperture Size
Aperture size is a vital dimension in any tympanic tube. Aperture size of a tympanic tube
describes how large the pathway created between the middle ear and the ear canal will
be. Larger aperture sizes allow for larger particulate to enter the ear yet also have the
less likelihood of being blocked by ear fluid drainage. A major consideration with
aperture size is that an aperture has to be large enough to allow for middle ear fluid
drainage while also restricting the outside fluids and particulate that is able to enter the
ear. Testing was conducted to determine the ideal aperture size by using a thin
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elastomer sheet and varying aperture sizes. The specifics of this testing can be found in
section 6.1 of this document.

5.2 Intellectual Property
To protect the tympanic tube design created through this project, it was necessary to
secure the intellectual property of the design. A crucial factor considered was that this
commercialization process had to be repeatable. As such, it was necessary to find a
legal partner whom would agree to and have the capabilities to complete the legal work
for all devices using the proposed commercialization process. Most universities in the
United States offer patenting services to their students and faculty and have a set
budget, that varies between institutions, for this purpose. California Polytechnic State
University San Luis Obispo currently offers patenting to students as well. However, it
was determined that this route would not fit the needs of this commercialization pathway
because a large number of patents may be needed, and the university does not always
accept student patent proposals.

It is also necessary that teams that use this commercialization pathway determine if
extraordinary campus resources had been used in the product development.
Extraordinary resources are any machinery or tools that are extremely specialized.
General machine shop products and testing devices do not warrant extraordinary
resource usage in general. If extraordinary campus resources have been utilized, the
university will have a claim to the device and teams will need to approach the university
before intellectual property is assigned.

At California Polytechnic State University San Luis Obispo, Ideally, this entity would be a
university, as students of law as well as practicing lawyers are encouraged to work on
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legal documentation while attending law school; because of this, it would be possible to
allow for an agreement to be made where legal documentation could be traded for equity
in a company and legal documentation completion experience for law students. Being
that California Polytechnic State University San Luis Obispo does not bear a law school,
an outside legal partner was required.

The most tangible option for acquiring a legal partner was utilizing an American based
university that possessed a reputable law school. An agreement is to be made with this
university where Cal Poly SLO products would receive legal support including nondisclosure agreements and utility patents applications. In return, the law school involved
would receive a percent equity of each entity to which a patent application was
completed as well as real-life legal documentation experience for students.

Due to the high volume of projects that may utilize the proposed pathway, another legal
entity was needed. As such, two outside organizations that will be included in the
proposed commercialization process were identified. Both organizations would be given
equity of the company created around the legal work completed.

5.3 Manufacturing
Medical devices require that their manufacturer is International Organization for
Standardization (ISO) 13485 certified. ISO 13485 outlines the quality management
systems that must be in place for a manufacturer to produce medical devices36. As such,
it was necessary to locate a manufacturer that was ISO 13485 certified and also able to
produce the tympanic tube. It was determined that injection molding would be used to
produce the tympanic tube as it allows for a rapid and mass production of tubes.
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Tympanic tubes are exceptionally small in size and it became evident that not all
manufacturers were equipped to produce this type of device. It should be noted that
within the field of medical devices, there is a huge range of products that will each
require specialized manufacturers to be produced. Due to this factor, it is impossible to
secure a single manufacturer to produce all devices that will utilize the proposed
commercialization path. This portion of the path is therefore not standardized and each
individual project group must locate a manufacturer that is able to meet their specific
produce needs.

Future efforts will be directed to creating a Cal Poly SLO ISO 13485 manufacturing
plant. Such a facility would allow for products on the proposed commercialization route
to have access to a manufacturing plant. This facility would allow for the same
manufacturer to be used on all medical device projects aiming for commercialization
created at Cal Poly SLO.

5.4 FDA Approval
FDA approval is one of the largest hurdles when attempting to commercialize a medical
product. In order to secure FDA approval, it was necessary to identify what approval
path the tympanic tube would be required to complete. By using the FDA’s small
business assistance helplines, it was determined that the device would require the
510(k) pathway. An initial draft of the 510(k) submission was completed. Often, entities
are required to submit, revise, and resubmit their FDA approval applications; this can be
a costly and time-consuming process. To minimize the possibility of the tympanic tube
510(k) application being rejected, it was decided that participating in the Q-Substitution
program with the FDA would be the best course of action. The Q-Substitution program
allows those hoping to receive FDA approval to meet with the team that will be
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responsible for reviewing their application once submitted. Companies are able to
receive feedback on their application and answer to specific questions. Participation in
this program helps to better the likelihood of gaining FDA approval.

It was soon realized that because of the complexities surrounding FDA approval,
possessing an FDA consultant would be vital to the rapid commercialization of the
products on the proposed commercialization pathway. Onboarding an FDA consultant
would assist in creating a repeatable commercialization process. In one embodiment of
the commercialization plan, for her consulting, she would be given $10,000 and a portion
of equity in the company for which she provided consulting for.

5.5 Funding
The tympanic tube device was initially funded through the Biomedical Engineering
Department at Cal Poly SLO’s senior project program as well as through the company
owner. Various pathways exist to secure funding means through the acquisition of
investors. One potential route is the Cal Poly Center for Innovation and Entrepreneurship
(CIE). This center works closely with Cal Poly SLO to assist students in advancing their
entrepreneurial endeavors. Due to the already present relationship, including the Cal
Poly CIE, would allow for this process to repeat and become a part of the proposed
commercialization pathway.

An investor deck, that contained all relevant information about the tympanic tube and its
market need, was created and will be presented to Cal Poly linked investors in order to
secure funding for the continuation of the project.
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5.6 Marketing Plan
The plan for the marketing of the tympanic tube design discussed in this document
focuses largely on the use of medical device conferences. The American Academy of
Otolaryngology, Medtech Live, 10x Medical Device Conference, etc. were all
opportunities to market and showcase this device. Due to the COVID-19 situation and
the early stage that the tympanic tube device was in, attending such conferences was
not considered. However, in following years attending such conferences will be feasible.
For future devices that will follow the proposed commercialization pathway, attending
medical device conferences will serve as one means of marketing new medical devices
created at Cal Poly SLO. However, differing devices will be most effectively marketed at
conferences specific to the devices niche.
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Chapter 6
TESTING, EVALUATION, AND DISCUSSION
6.1 Resistance to Flow Testing
6.1.1 Test Rationale and Description
A critical design choice for the cross-flange tympanic tube design was the internal
aperture diameter. Because tympanic tubes are exposed to fluids other than inner ear
fluid, it is vital that the aperture prevents as much inflow of outside fluids as possible to
protect the middle ear. The aperture must also be large enough for middle ear fluid to
exit without clogging.

Figure 5. Flow Within the Implanted Tympanic Tube29
This was tested by using five different aperture sizes and three different fluid types. The
apertures were placed across the opening of a length of tubing which was filled with
fluid. The amount of water present in the line after one minute was recorded.

6.1.2 Methodology
In order to determine the needed aperture size, five potential aperture sizes were tested
using three different types of fluid to reveal which aperture size was best able to resist
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the flow of each fluid type. The five aperture sizes were as follows: .5 mm, 1 mm, 1.27
mm, 1.5 mm, and 2 mm. It should be noted that the most common industry standard for
the internal diameter of tympanic tubes is 1.27 mm. The three liquid types used to test
the apertures were room temperature tap water, soap water with a 16:1 ratio, and saltwater with a 4:1 ratio.

In order to create the varying aperture sizes, leather cutting tools and a syringe head
were used to cut the appropriately sized aperture into an elastomer film. Figure 6
illustrates the 5 different tools that were used to create the apertures.

Figure 6. Tools Used to Create Apertures and an Elastomer Sheet.
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Figure 7. Resistance to Flow Experimental Setup
Each elastomer sheet was placed at the end of a vertically oriented tube. 200 ml of fluid
was poured through a funnel into the tube and once pouring was complete, a one-minute
timer was started. The height of the fluid present in the tube after the one minute had
passed was recorded. This process was repeated 5 times for each aperture size with
each of the different fluid types resulting in 75 data points. Statistical analysis was
conducted on the data using an ANOVA and Tukey post hoc to determine if there were
significant differences in the yielded results.

6.1.3 Results and Discussion
A summary of results from the aperture testing can be seen in Table 2. The full dataset
can be seen in Appendix I.
Table 2. Average Height in mm of Water Present in Tube.
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To determine the differences between the flow resistance between aperture sizes, a
repeated measures ANOVA with a Tukey post hoc test was performed and the results
are show In Table 3. The complete statistical analysis can be found in Appendix II.

Table 3. Tukey Post Hoc Data for the Fluid Height Compared to Aperture Size.

Through the statistical analysis, it was found that of the five different aperture sizes,
there were three distinct groups in respect to fluid height recorded in the tube. The 0.5
mm aperture was able to hold the greatest amount of fluid overall and it held significantly
greater millimeters of fluid than all other aperture sizes. The 1.00 mm and 1.27 mm
apertures held the second greatest amount of fluid and these apertures did not perform
significantly different from one another. These two aperture sizes were able to hold a
significantly less amount of fluid than the 0.5 aperture and significantly more than the 1.5
mm and 2.0 mm apertures. The 1.5 mm and 2.00 mm apertures held the least amount of
fluid and did not perform significantly different from one another.

As a result of this analysis, it was clear that choosing the 0.5 mm aperture would allow
for the least amount of fluid to enter the aperture. Another viable choice was either the
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1.00 mm or 1.27 mm aperture sizes because these apertures held the second greatest
amount of fluid and are more comparable to current industry standards.

6.2 Tympanic Membrane Natural Frequency Testing
6.2.1 Test Rationale and Description
An area of concern with the cross-flange tympanic tube design created was that it might
impede on the natural vibrational patterns of the tympanic membrane. There is currently
limited data that explores the effects of tympanic tubes on the tympanic membrane’s
vibrational pattern. As such, it was necessary to explore how a competitor tube effects
the tympanic membrane and assess how the newly designed tube compares to the
competitor tube.

The test used to explore the vibrational patterns of the tympanic membrane is commonly
known as a pop-test36. This test requires that the membrane of interest be stretched
under pressure and then popped. A pressure transducer used was to record how the
pressure changed as the membrane popped. This data was to be used to describe the
vibrational properties of the membrane. A Fast Fourier Transform (FFT) was be applied
to the pressure data and the frequency response was determined as well as the energy
associated with the vibrations.

6.2.2 Methodology
To create the experimental setup, a hard-plastic container was used to create a pressure
chamber. The Utah Medical Deltran® Disposable Pressure Transducer was attached to
the chamber as well as a hand pump and pressure gauge. The pressure transducer was
connected to the BioPac MP160 data acquisition system. The experimental setup can be
seen in Figure 8.
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Figure 8. Pop-Test Experimental Setup
The membrane that was used to mimic the tympanic membrane was saran wrap. The
membrane was stretched over the main opening of the pressure chamber. In order to
insert the tympanic tube, a pin was used to create a small opening in the membrane and
the tube was inserted using small grips. In order to help seal the chamber, glue was
used to attach the tube to the membrane and a small piece of saran wrap was used to
seal the internal aperture of the tympanic tube.

Figure 9. Membrane With and Without a Tympanic Tube Inserted.
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Once the membrane was in place, the data acquisition system was setup to gather
pressure data from one channel. The reading was calibrated using the pressure gauge
connected to the chamber to ensure that the correct pressure was reported. 125 ml of
water was placed inside the plastic container and pressure was applied to the system
using the attached handpump. Once the system reached 20 mmHg, a pin was used to
pop the membrane.

Figure 10. Membrane Stretch as Pressure is Applied.
This test was conducted with three different membrane treatments. The membrane
without any tube inserted (natural response), the membrane with the competitor tube
inserted, and the membrane with a 3D printed prototype of the cross-flange tympanic
tube.

Figure 11. 3D-Printed Cross Flange Tube Utilized During Pop-Testing.
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6.2.3 Results and Discussion
A sample of raw pressure data and FFT data acquired from the BioPac system is shown
in Figure 12 below. A summary of results from the aperture testing can be seen in Table
4.

Figure 12. Raw Pressure (Top) and FFT Data (Bottom) From Pop-Test.
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Table 4. Pop-Test Data and Calculated Averages.

To determine the differences between the frequency response and vibrational energy
between different membrane treatments, a repeated measures ANOVA with a Tukey
post hoc test was performed and the results are shown in Table 5.

Table 5. Pop-Test Statistical Analysis.
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Through the Tukey comparison, it was revealed that none of the membrane treatments
had a significantly different Frequency response. However, when looking at the
averages it should be noted that the Cross-Flange tube had a higher frequency
response than the competitor tube. Additionally, it can be seen that the Cross-Flange
tube had a significantly similar vibrational energy to the natural response as well as the
competitor response. A successful vibrational energy response, with a tympanic tube
implanted in the membrane, would either be equal to or greater than the natural
response. It was revealed that the competitor tube had a significantly lower vibrational
energy than the natural response.

These frequency results are promising for the Cross-Flange tympanic tube. Because this
newly designed tube had a similar frequency response to that of the competitor tube and
natural membrane, the new design does not significantly affect the frequency response
of the membrane. Theoretically, this would mean that the newly designed tube would not
significantly alter the hearing of a patient with a tympanic tube. The vibrational energy
results are also promising. The Cross-Flange design had a vibrational energy not
statistically different than that of the natural membrane further illustrating that the new
tube does not significantly affect the vibrations of the membrane. The Cross- Flange
design actually out-performed the competitor tube, which had a significantly different
vibrational energy than the natural membrane. Overall, from this testing it is clear that
the Cross-Flange tube is a design that will not negatively affect the vibrations of the
tympanic membrane.

36

Chapter 7
COMMERCIALIZATION METHOD DESCRIPTION
7.1 Device Optimization
Students and groups whom are producing medical devices at Cal Poly will largely be
responsible for identifying and performing the necessary testing to ensure a quality
device. These individuals will have access to Cal Poly SLO laboratories and equipment
as needed to complete said testing as well as be able to connect with key opinion
leaders through Cal Poly faculty and French Hospital that will assist in identifying product
testing. The project’s FDA consultant, described in greater detail below, will also be at
the creator’s disposal to assist in determining the necessary qualifications of a device to
ensure it is able to be FDA approved.

7.2 Intellectual Property
The intellectual property of medical devices created at Cal Poly that are brought down
this pathway will be granted with the assistance of a newly created patent clinic. This
patent clinic will function to create a reliable and repeatable process, allowing for Cal
Poly SLO students as well as individuals in the community to seek legal assistance. The
patent clinic will receive a percent equity of each of the projects that become involved
with the clinic. Such revenues would be recycled back into the surrounding community to
create jobs, provide community funding, and help those in need in a community. An
entity shall be created surrounding the patent clinic and the necessary legal team will be
established. Lawyers completing the legal documentation may be students seeking
experience or currently practicing patent lawyers.
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7.3 Manufacturing
Devices that use the proposed commercialization pathway will seek manufacturing
services from a certified ISO 13845 facility. It is impossible to assign one manufacturer
to all devices on this pathway as different manufacturing facilities specialize in different
types of production. However, as more projects utilize this pathway, agreements
between manufacturers and Cal Poly SLO can be created to produce a list of potential
manufacturers that form an alliance with Cal Pol SLO. Eventually it is hoped that Cal
Poly SLO will possess its own manufacturing plant where such products can be
produced.

7.4 FDA Approval
FDA approval is generally one of the largest hurdles a medical device must overcome to
become commercialized. Medical devices that used the proposed pathway will be
evaluated by an FDA consultation to ensure that devices are given the best possible
chance of receiving FDA approval as possible. The consultant will provide their expertise
to determine the necessary approval route that needs to be taken as well as be available
to assist with the completion of the approval application. The consultant will help to
determine what testing might be necessary as a part of the approval process as well.
Overall, the consultant will function as a means to understand the complexities of
applying for FDA approval in reference to a project’s specific needs.

After the FDA consultant’s evaluation and advice has been incorporated into the FDA
approval application, a Q-sub meeting will be scheduled by the device creators. The Qsub meeting serves as a means for those hoping to receive FDA approval to seek advice
and knowledge from the direct FDA team that will evaluate their approval application. A
template Q-Sub meeting request form can be viewed in Appendix III.
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7.5 Funding
Medical devices that go down the proposed pathway will gain funding through investors.
The device creators will create an investor deck which will depict their ideas to investors
in the hopes of encouraging interest in the device. An investor deck outline is included in
Appendix IV of this document.

Various pathways exist for Cal Poly to secure equity, two options are as follows:
1) Cal Poly is given first bid on company ownership. Students will present their
investor deck to Cal Poly representative’s first and Cal Poly will have the first
opportunity to invest and secure equity.
2) Cal Poly will receive equity in the company. This percentage would be equal for
any and all devices that use the proposed commercialization method.

7.6 Marketing Plan
Student created medical devices that choose to use the proposed commercialization
pathway will attend relevant medical conferences. Funding acquired from investors will
fund the attendance of such conferences.
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Chapter 8
SUMMARY AND CONCLUSION
8.1 Work Relevance
This project helps to lay the foundation in creating a process that allows medical devices
made at Cal Poly SLO to be commercialized. California Polytechnic State University San
Luis Obispo’s Biomedical Engineering Department presents numerous opportunities
where students can combine their efforts with faculty and industry needs to create
valuable medical technology. However, many of the student created medical devices
never make it into the global market due to the challenges surrounding the
commercialization process. The devices created at Cal Poly SLO are often cutting-edge
technology that can have the potential to change the lives of many for the better.
Creating a process to assist in the commercialization of medical products made at Cal
Poly SLO will help to grow the world of biotechnology and place student devices in the
market.

8.2 Project Limitations
The most limiting factor of this project was the timeline. The time required in creating
agreements between parties and drafting and finalizing contracts is enormous. Due to
the COVID-19 situation, certain timelines were extended and as a result, not all aspects
of this process were finalized.

8.3 Future Steps
Through the efforts put into this project, potential commercialization pathways were
explored. Due to the nature of the formation of this type of pathway, not all aspects of
the process were determined, and finalization of certain aspects are needed before this
pathway is able to support a large influx of student created devices.
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A major step that will need to be taken is further development of the patent clinic. It will
be necessary to secure a set legal team in order to ensure that access to a legal team
become a repeatable and reliable portion of this process. It will be necessary to form an
entity surrounding the patent clinic to continue its development.

Although the securement of manufacturers for proposed devices is easily attained
through the numerous ISO certified manufacturers available, a long-term consideration
may be for Cal Poly to create its own manufacturing plant. This would create student and
community jobs and provide a way for Cal poly to move manufacturing capabilities inhouse. A potential cite for this plant may be the Diablo Canyon ex-power plant as this is
an enormous facility that currently has no use.

Marketing was an aspect of this process that was largely underdeveloped. It would be
necessary for future work to create a robust marketing plan to ensure that created
devices are given as much exposure as possible.
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APPENDICES
A
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B
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C

47

D

Investor Deck Outline
Team Members & Contact Info
Include relevant team member information and if applicable, expertise relevant to the
project
Indications for Use (IFU) & Device Background
Give context to the device and its usage, assume audience has a minimal knowledge of
device
Product Renditions
Provide product visualizations and if possible, prototypes
Product Market Analysis
Present the current market value of device
Market Advantage
Highlight unique aspects of product that make it a competitive product
Required Funding
Provide a breakdown of the necessary costs that will be required for the project
Future of Device
Include the next steps the device will need to undergo and future goals
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